Brokers Set Expectations for Kiora Pharmaceuticals, Inc.’s Q2 2024 Earnings (NASDAQ:KPRX)

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) – HC Wainwright lowered their Q2 2024 earnings per share estimates for Kiora Pharmaceuticals in a research report issued on Monday, July 22nd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.95) for the quarter, down from their prior estimate of ($0.81). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $0.97 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at $1.31 EPS, Q1 2025 earnings at ($0.67) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($2.66) EPS.

Separately, Maxim Group raised Kiora Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, June 13th.

Kiora Pharmaceuticals Price Performance

Shares of Kiora Pharmaceuticals stock opened at $4.69 on Wednesday. Kiora Pharmaceuticals has a 52 week low of $3.60 and a 52 week high of $8.98. The stock has a 50 day moving average price of $5.23 and a two-hundred day moving average price of $5.30.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its quarterly earnings data on Friday, May 10th. The company reported $3.42 EPS for the quarter, missing analysts’ consensus estimates of $5.58 by ($2.16). The business had revenue of $16.00 million during the quarter, compared to analysts’ expectations of $16.00 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. purchased a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals accounts for approximately 1.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 22nd biggest holding. Rosalind Advisors Inc. owned approximately 8.76% of Kiora Pharmaceuticals as of its most recent SEC filing. 76.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Erin Parsons bought 5,260 shares of the company’s stock in a transaction dated Thursday, June 13th. The shares were bought at an average price of $4.88 per share, for a total transaction of $25,668.80. Following the completion of the acquisition, the director now directly owns 5,260 shares of the company’s stock, valued at $25,668.80. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have purchased 9,791 shares of company stock worth $48,764 over the last 90 days. 0.94% of the stock is currently owned by corporate insiders.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.